Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

Click here now to download the free Precious Metals Buying Guide!

Sadie Stern Biography and Net Worth

EVP of DexCom

Sadie Stern is Executive Vice President and Chief Human Resources Officer at Dexcom.

In this role, Sadie is responsible for Dexcom’s People Strategy. She leads the Global Human Resources function, including Diversity, Equity and Inclusion; Total Rewards; Talent Acquisition; Talent Development; Organization Effectiveness; and HR Operations. She also serves as the strategic business partner to Dexcom’s Executive Committee.

With more than 20 years of experience in Human Resources, she has led global organizations through growth and change. Prior to Dexcom, she served as Executive Vice President, People and Culture at 3D Systems, overseeing all aspects of Human Resources across the company’s operations in 23 countries. Sadie has also worked at Qualcomm, LG Electronics and The Walt Disney Company, leading HR teams and driving organizational transformation.

She holds a Master of Arts in Higher Education from the University of Denver, and a Bachelor of Arts in English from San Diego State University.

What is Sadie Stern's net worth?: The estimated net worth of Sadie Stern is at least $9.89 million as of March 25th, 2024. Ms. Stern owns 76,304 shares of DexCom stock worth more than $9,893,577 as of April 19th. This net worth evaluation does not reflect any other assets that Ms. Stern may own. Learn More about Sadie Stern's net worth.
How old is Sadie Stern?: Ms. Stern is currently 49 years old. There are 7 older executives and no younger executives at DexCom. The oldest executive at DexCom is Mr. Kevin Ronald Sayer, Executive Chairman, CEO & President, who is 66 years old. Learn More on Sadie Stern's age.
How do I contact Sadie Stern?: The corporate mailing address for Ms. Stern and other DexCom executives is 6340 SEQUENCE DRIVE, SAN DIEGO CA, 92121. DexCom can also be reached via phone at (858) 200-0200 and via email at [email protected]. Learn More on Sadie Stern's contact information.
Has Sadie Stern been buying or selling shares of DexCom?: Sadie Stern has not been actively trading shares of DexCom over the course of the past ninety days. Most recently, Sadie Stern sold 4,137 shares of the business's stock in a transaction on Monday, March 25th. The shares were sold at an average price of $140.00, for a transaction totalling $579,180.00. Following the completion of the sale, the executive vice president now directly owns 76,304 shares of the company's stock, valued at $10,682,560. Learn More on Sadie Stern's trading history.
Who are DexCom's active insiders?: DexCom's insider roster includes Donald Abbey (EVP), Steven Altman (Director), Nicholas Augustinos (Director), Andrew Balo (Insider), Quentin Blackford (COO), Michael Brown (EVP), Richard Collins (Director), Matthew Dolan (SVP), Richard Doubleday (EVP), Paul Flynn (EVP), Mark Foletta (Director), Bridgette Heller (Director), Barbara Kahn (Director), Jacob Leach (EVP), Jeffrey Moy (EVP), Patrick Murphy (EVP), Steven Pacelli (Insider), Chad Patterson (EVP), Barry Regan (EVP), Kevin Sayer (CEO), Shelly Selvaraj (SVP), Sumi Shrishrimal (SVP), Jay Skyler (Director), Sadie Stern (EVP), and Jereme Sylvain (CAO). Learn More on DexCom's active insiders.
Are insiders buying or selling shares of DexCom?: During the last twelve months, insiders at the medical device company sold shares 43 times. They sold a total of 305,791 shares worth more than $39,737,753.55. The most recent insider tranaction occured on April, 15th when EVP Matthew Vincent Dolan sold 1,990 shares worth more than $274,241.90. Insiders at DexCom own 0.4% of the company. Learn More about insider trades at DexCom.
Information on this page was last updated on 4/15/2024.

Sadie Stern Insider Trading History at DexCom

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/25/2024	Sell	4,137	$140.00	$579,180.00	76,304
3/12/2024	Sell	20,321	$133.61	$2,715,088.81	80,441
1/16/2024	Sell	2,902	$123.63	$358,774.26	79,051
12/11/2023	Sell	392	$117.66	$46,122.72	76,008
11/22/2023	Sell	1,176	$110.00	$129,360.00	76,400
8/9/2023	Sell	392	$110.71	$43,398.32	81,682
7/10/2023	Sell	392	$128.05	$50,195.60	82,074
6/9/2023	Sell	393	$121.31	$47,674.83	82,466
5/9/2023	Sell	393	$120.19	$47,234.67	82,859
4/10/2023	Sell	393	$112.35	$44,153.55	83,252
11/22/2021	Sell	856	$638.65	$546,684.40

Sadie Stern Buying and Selling Activity at DexCom

DexCom Company Overview

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.

Today's Range

Now: $130.71

$129.18

$135.06

50 Day Range

MA: $129.35

$114.22

$140.45

2 Week Range

Now: $130.71

$74.75

$142.00

Volume

2,859,523 shs

Average Volume

2,982,438 shs

Market Capitalization

$50.39 billion

P/E Ratio

99.78

Dividend Yield

N/A

Beta

1.2

The “Perfect Storm” for Gold

From Gold Safe Exchange | Ad